Table 1.
Patient characteristics
| Clinical characteristics | No. of Patients (%) | P* | No. of Patients (%) | P** | ||
|---|---|---|---|---|---|---|
| PD‐IDC, n = 1569 |
IDC, n = 467 004 |
PD‐DCIS, n = 1489 |
DCIS, n = 144 699 |
|||
|
Age at diagnosis Mean ± SD, y |
59.91 ± 15.286 | 59.36 ± 13.531 | 0.158 | 63.17 ± 14.611 | 58.84 ± 12.154 | <0.001 |
| Race | <0.001 | <0.001 | ||||
| White | 1016 (64.8%) | 330 024 (70.7%) | 1234 (82.9%) | 112 381 (77.7%) | ||
| Black | 190 (12.1%) | 47 599 (10.2%) | 128 (8.6%) | 15 720 (10.9%) | ||
| Hispanic/Other/Unknown | 363 (23.1%) | 89 381 (19.1%) | 127 (8.5%) | 16 598 (11.5%) | ||
| Laterality | 0.441 | 0.011 | ||||
| Left | 809 (51.6%) | 236 354 (50.6%) | 811 (54.5%) | 73 983 (51.1%) | ||
| Right | 759 (48.4%) | 230 572 (49.4%) | 678 (45.5%) | 70 673 (48.9%) | ||
| Tumor location | <0.001 | <0.001 | ||||
| Central/NAC | 440 (38.2%) | 24 465 (5.9%) | 949 (78.4%) | 10 564 (8.7%) | ||
| Upper inner quadrant | 76 (6.6%) | 56 602 (13.7%) | 15 (1.2%) | 12 411 (10.3%) | ||
| Lower inner quadrant | 61 (5.3%) | 27 422 (6.6%) | 26 (2.1%) | 9302 (7.7%) | ||
| Upper outer quadrant | 243 (21.1%) | 169 194 (40.9%) | 66 (5.5%) | 47 270 (39.1%) | ||
| Lower outer quadrant | 70 (6.1%) | 34 087 (8.2%) | 31 (2.6%) | 10 207 (8.4%) | ||
| Overlapping lesion | 262 (22.7%) | 101 917 (24.6%) | 123 (10.2%) | 31 167 (25.8%) | ||
| Tumor grade | <0.001 | <0.001 | ||||
| Grade I | 101 (6.4%) | 92 245 (19.8%) | 21 (1.9%) | 17 236 (13.9%) | ||
| Grade II | 502 (32.0%) | 192 403 (41.2%) | 168 (15.6%) | 51 112 (41.1%) | ||
| Grade III | 934 (59.5%) | 178 023 (38.1%) | 640 (59.4%) | 42 609 (34.2%) | ||
| Grade IV | 32 (2.0%) | 4333 (0.9%) | 248 (23.0%) | 13 476 (10.8%) | ||
| AJCC sixth edition stage | <0.001 | <0.001 | ||||
| 0 | 0 (0%) | 0 (0%) | 1149 (83.1%) | 144 699 (100.0%) | ||
| I | 555 (35.6%) | 236 401 (50.6%) | 133 (9.6%) | 0 (0%) | ||
| II | 547 (35.1%) | 174 292 (37.3%) | 72 (5.2%) | 0 (0%) | ||
| III | 457 (29.3%) | 56 299 (12.1%) | 28 (2.0%) | 0 (0%) | ||
| T | <0.001 | <0.001 | ||||
| T0 | 0 (0%) | 0 (0%) | 1151 (83.3%) | 144 699 (100.0%) | ||
| T1 | 801 (51.5%) | 297 117 (63.7%) | 149 (10.8%) | 0 (0%) | ||
| T2 | 477 (30.7%) | 139 192 (29.9%) | 44 (3.2%) | 0 (0%) | ||
| T3 | 113 (7.3%) | 19 414 (4.2%) | 19 (1.4%) | 0 (0%) | ||
| T4 | 163 (10.5%) | 10 578 (2.3%) | 19 (1.4%) | 0 (0%) | ||
| N | <0.001 | <0.001 | ||||
| N0 | 785 (50.0%) | 313 992 (67.2%) | 1340 (97.4%) | 144 699 (100.0%) | ||
| N1 | 471 (30.0%) | 109 931 (23.5%) | 26 (1.9%) | 0 (0%) | ||
| N2 | 194 (12.4%) | 28 708 (6.1%) | 7 (0.5%) | 0 (0%) | ||
| N3 | 119 (7.6%) | 14 373 (3.1%) | 3 (0.2%) | 0 (0%) | ||
| Hormone receptor status | <0.001 | <0.001 | ||||
| ER+/PR+ | 498 (35.5%) | 291 341 (66.6%) | 181 (19.7%) | 70 545 (74.4%) | ||
| ER+/PR‐ | 235 (16.7%) | 50 225 (11.5%) | 143 (15.6%) | 10 159 (10.7%) | ||
| ER‐/PR+ | 49 (3.5%) | 5741 (1.3%) | 31 (3.4%) | 817 (0.9%) | ||
| ER‐/PR‐ | 622 (44.3%) | 90 020 (20.6%) | 564 (61.4%) | 13 351 (14.1%) | ||
| HER2 statusa | <0.001 | <0.001 | ||||
| Positive | 254 (63.5%) | 30 223 (16.7%) | 84 (83.2%) | 2313 (32.4%) | ||
| Negative | 146 (36.5%) | 151 053 (83.3%) | 17 (16.8%) | 4831 (67.6%) | ||
| Molecular subtypea | <0.001 | <0.001 | ||||
| HR+/Her2‐ | 121 (30.5%) | 128 129 (70.8%) | 10 (10.0%) | 4405 (62.0%) | ||
| HR+/Her2+ | 132 (33.2%) | 21 112 (11.7%) | 25 (25.0%) | 1544 (21.7%) | ||
| HR‐/Her2+ | 119 (30.0%) | 9064 (5.0%) | 58 (58.0%) | 752 (10.6%) | ||
| HR‐/Her2‐ | 25 (6.3%) | 22 767 (12.6%) | 7 (7.0%) | 400 (5.6%) | ||
| Surgery | <0.001 | <0.001 | ||||
| Partial mastectomy | 171 (10.9%) | 277 695 (59.6%) | 483 (32.6%) | 103 613 (71.8%) | ||
| Mastectomy | 1394 (89.1%) | 188 167 (40.4%) | 1000 (67.4%) | 40 720 (28.2%) | ||
| Chemotherapy | <0.001 | <0.001 | ||||
| Yes | 841 (53.6%) | 206 903 (44.3%) | 53 (3.6%) | 1038 (0.7%) | ||
| No | 728 (46.4%) | 260 101 (55.7%) | 1436 (96.4%) | 143 661 (99.3%) | ||
| Radiotherapy | <0.001 | <0.001 | ||||
| Yes | 425 (27.1%) | 252 220 (54.0%) | 297 (19.9%) | 67 811 (46.9%) | ||
| No | 1144 (72.9%) | 214 784 (46.0%) | 1192 (80.1%) | 76 888 (53.1%) | ||
Abbreviations: AJCC, American Joint Committee on Cancer; DCIS, ductal carcinoma in situ; ER, estrogen receptor; HER2, human epidermal receptor‐2; HR, Hormone receptor; IDC, invasive ductal carcinoma; NAC, nipple‐areola complex; PD‐DCIS, Paget disease with ductal carcinoma in situ; PD‐IDC, Paget disease with invasive ductal carcinoma; PR, progesterone receptor; +, positive; and ‐, negative
a
HER2 status and molecular subtype data were available for only the patients who were diagnosed between 2010 and 2015.